Evaluation of Vav3.1 as prognostic marker in endometrial cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10383442" target="_blank" >RIV/00216208:11140/18:10383442 - isvavai.cz</a>
Result on the web
<a href="https://link.springer.com/content/pdf/10.1007%2Fs00432-018-2725-2.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007%2Fs00432-018-2725-2.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00432-018-2725-2" target="_blank" >10.1007/s00432-018-2725-2</a>
Alternative languages
Result language
angličtina
Original language name
Evaluation of Vav3.1 as prognostic marker in endometrial cancer
Original language description
Vav3 is a guanine nucleotide exchange factor that regulates the activity of Rho/Rac family GTPases. In a study on ovarian cancer, we recently demonstrated pronounced prognostic and predictive value of Vav3.1, a specific truncation variant of the parental Vav3 gene. Here, we sought to investigate the role of Vav3.1 in the most prevalent gynecological tumor entity, endometrial cancer. Vav3.1 transcript levels were determined in a large cohort of endometrial cancer patients using variant-specific PCR (n = 239), and non-malignant endometrial tissue served as control (n = 26). Expression levels of Vav3.1 were stratified according to established clinicopathological characteristics and correlated to long-term patient survival (average follow-up of > 7.5 years). Type 1 and type 2 cancers were separately investigated. While Vav3.1 was markedly overexpressed in endometrial cancer tissue, we could not detect associations with clinical parameters related to prognosis, such as FIGO stage and tumor grade. Kaplan-Meier estimators of different measures of survival failed to show prognostic significance of Vav3.1 in endometrial cancer. Lack of prognostic value was observed for both type 1 and type 2 cancers. Our study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Cancer Research and Clinical Oncology
ISSN
0171-5216
e-ISSN
—
Volume of the periodical
144
Issue of the periodical within the volume
10
Country of publishing house
DE - GERMANY
Number of pages
10
Pages from-to
2067-2076
UT code for WoS article
000446056200019
EID of the result in the Scopus database
2-s2.0-85052068927